Investment Thesis
CG Oncology faces critical financial distress with annual operating cash burn of $57.2M against only $33.7M in cash reserves, yielding a runway of approximately 7 months at current burn rate. Minimal revenue of $1.1M is dwarfed by operating losses of $66.4M, indicating the company is not approaching profitability in any near-term scenario. Without immediate capital infusion or dramatic operational improvement, the company faces severe liquidity constraints.
Strengths
- Minimal debt leverage (0.00x Debt/Equity ratio) reduces financial obligations
- Strong balance sheet structure with $1.1B in total assets and low liabilities of $43.5M
- Exceptional current ratio of 31.3x and quick ratio of 31.25x on paper indicating short-term liquidity
Risks
- Critical cash burn: Operating cash flow of -$56.9M annually against only $33.7M cash reserves (sub-7 month runway)
- Deeply unprofitable with net income of -$60.2M and net margin of -5558%, showing no path to near-term profitability
- Minimal revenue base of $1.1M cannot support current operating structure; massive operating losses of $66.4M indicate fundamental business model issues
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue growth trajectory and timeline to positive operating cash flow
- Capital raise announcements and debt issuance (funding urgency indicator)
Financial Metrics
Revenue
1.1M
Net Income
-60.2M
EPS (Diluted)
$-0.71
Free Cash Flow
-57.2M
Total Assets
1.1B
Cash
33.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-6,130.1%
Net Margin
-5,558.8%
ROE
-5.5%
ROA
-5.3%
FCF Margin
-5,286.0%
Balance Sheet & Liquidity
Current Ratio
31.30x
Quick Ratio
31.25x
Debt/Equity
0.00x
Debt/Assets
3.8%
Interest Coverage
N/A
Long-term Debt
3.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:06:07.048699 |
Data as of: 2026-03-31 |
Powered by Claude AI